根据每个国家的需求和实际情况制定丙型肝炎消除方案

摘要/Abstract

摘要： 丙型肝炎病毒感染是各国面临的一项重大公共卫生问题,直接抗病毒药物治疗有效地提高了丙型肝炎患者的治愈率和病毒应答率。治疗时间短,耐受性好,是治疗丙型肝炎的首选方案。2016年,世界卫生组织提出,截止2030年全球“消除丙型肝炎”的倡议,将慢性肝炎感染的发病人数从目前的600~1000万例减少到90万例,年死亡人数从140万例减少到50万例以下,然而仅个别国家有望达成此目标。各国应依据丙型肝炎在国家和地区的流行情况,结合国情,制定相应的公共卫生策略。加强丙型肝炎健康知识教育,加强人群筛查,关注重点人群,缩短诊断时间,获得治疗机会,将HCV感染患者与护理联系起来。

关键词: 丙型肝炎, 丙型肝炎病毒, 直接抗病毒药物, 筛查, 消除

王昕, 饶慧瑛. 根据每个国家的需求和实际情况制定丙型肝炎消除方案[J]. 肝脏, 2024, 29(9): 1017-1018.

/ 推荐

参考文献

[1] Martinello M, Solomon S S, Terrault N A, et al. Hepatitis C[J]. Lancet, 2023, 402: 1085-1096.
[2] Taha G, Ezra L, Abu-Freha N. Hepatitis C Elimination: Opportunities and Challenges in 2023[J]. Viruses, 2023, 15: 1413.
[3] Di Marco L, La Mantia C, Di Marco V. Hepatitis C: Standard of Treatment and What to Do for Global Elimination[J]. Viruses, 2022, 14(3): 505.
[4] Cui F, Blach S, Manzengo Mingiedi C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C[J]. Lancet Gastroenterol Hepatol, 2023, 8: 332-342.
[5] Calvaruso V, Petta S, Craxì A. Is global elimination of HCV realistic?[J]. Liver Int, 2018, 38 Suppl 1: 40-46.
[6] Kondili L A, Craxi A. Hepatitis C elimination: Tailoring the approach to each country’s needs and realities[J]. Hepatology, 2024, 80: 263-265.
[7] Kondili L A, Craxì A, Aghemo A. Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements[J]. Liver Int, 2021, 41: 649-655.
[8] Tian F, Forouzannia F, Feng Z, et al. Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries[J]. Hepatology, 2024,80:440-450.
[9] Wang Y, Cheng G, Lau G. Achieving WHO target of HCV control in Hong Kong: challenges and strategies[J]. Global Health & Medicine, 2021, 3: 276-282.
[10] Huang CF, Chen GJ, Hung CC, et al. HCV Microelimination for High-risk Special Populations[J]. J Infect Dis, 2023, 228:S168-S179.
[11] Midgard H, Weir A, Palmateer N, et al. HCV epidemiology in high-risk groups and the risk of reinfection[J]. J Hepatol, 2016, 65: S33-S45.
[12] Warkad S D, Nimse S B, Song K S, et al. HCV Detection, Discrimination, and Genotyping Technologies[J]. Sensors, 2018, 18: 3423.
[13] Chevaliez S. Strategies for the improvement of HCV testing and diagnosis[J]. Expert Rev Anti Infect Ther, 2019, 17: 341-347.
[14] Fiore V, Manca V, Colpani A, et al. Facing HCV as a Major Public Healthcare Threat in Italy: Epidemiology and Micro-Elimination Pathways among Underserved Populations[J]. Healthcare, 2023, 11: 2109.
[15] Isakov V, Nikityuk D. Elimination of HCV in Russia: Barriers and Perspective[J]. Viruses, 2022, 14: 790.
[16] Nevola R, Rosato V, Conturso V, et al. Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies[J]. Biology,2022,11:805.
[17] Vo-Quang E, Pawlotsky J M. 'Unusual' HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment[J]. Gut, 2024, 73: 1570-1582.
[18] European Association For The Study Of The Liver . Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series'[J]. J Hepatol, 2023, 78: 452.
[19] Rockstroh J K, Swan T, Chang J, et al. The path to hepatitis C elimination: who are we leaving behind and why[J] ? J Int AIDS Soc, 2023, 26: e26136.
[20] Kondili LA, Craxì A, Aghemo A. Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements[J]. Liver Int, 2021,41(4):649-655.